NS
VERV

NBC Securities’s Verve Therapeutics VERV Stock Holding History

NBC Securities’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-350
Closed -$3K – 2872
2025
Q2 		$3K Sell
350
-150
-30% -$855 ﹤0.01% 2254
2025
Q1 		$2K Buy
+500
New +$3.35K ﹤0.01% 2056
2024
Q4 		– Sell
-350
Closed -$1K – 2048
2024
Q3 		$1K Buy
+350
New +$2.03K ﹤0.01% 2106
2024
Q2 		– Sell
-150
Closed -$1K – 2205
2024
Q1 		$1K Hold
150
– – ﹤0.01% 2142
2023
Q4 		$2K Hold
150
– – ﹤0.01% 2040
2023
Q3 		$1K Buy
+150
New +$2.42K ﹤0.01% 2095

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

NBC Securities's VERV Position: Q3 2025 in Review

NBC Securities sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 350 shares — an estimated $3K sold.

NBC Securities first reported a position in VERV in Q3 2023 and held it in 6 quarters. The position peaked at $3K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • NBC Securities reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • NBC Securities sold 350 Verve Therapeutics shares in Q3 2025, an estimated $3K.
  • NBC Securities first reported a position in Verve Therapeutics in Q3 2023 and held it in 6 quarters.
  • NBC Securities's Verve Therapeutics position peaked at $3K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on NBC Securities's 13F filing for Q3 2025, filed 14 Nov 2025.